文献速递头颈外科

治疗前格拉斯哥预后评分对晚期头颈癌同步放化疗耐受性、毒性及生存的影响

Impact of the pretreatment Glasgow prognostic score on treatment tolerance, toxicities, and survival in patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy.
PubMed 文献 · Head Neck · 2017-07-07

该回顾性研究分析了143例III、IVA、IVB期头颈癌患者,按治疗前格拉斯哥预后评分分组比较同步放化疗的毒性、耐受性和生存。结果显示评分越高,耐受性越差、体重下降和管饲需求更多、≥3级血液学毒性及脓毒症和毒性死亡比例更高,评分0分者总生存和无复发生存更优。

要点

  • 治疗前GPS评分与晚期肿瘤分期及T/N分类相关。
  • GPS评分高者同步放化疗耐受性差,体重下降和管饲需求更多。
  • GPS评分0分者总生存和无复发生存优于1或2分者。

核心结论

  • 治疗前格拉斯哥预后评分可预测晚期头颈癌同步放化疗的治疗耐受性、毒性和生存。

研究设计与样本

  • 回顾性分析2007至2010年143例III、IVA、IVB期头颈癌接受同步放化疗的患者,按格拉斯哥预后评分分组比较临床特征、毒性和生存。

主要发现

  • 格拉斯哥预后评分与晚期肿瘤分期及T/N分类相关。
  • 评分较高者耐受同步放化疗的可能性更低,体重下降更多,需要管饲支持更频繁。
  • 评分较高者≥3级血液学毒性、脓毒症和毒性死亡的比例更高。
  • 格拉斯哥预后评分为0的患者总生存和无复发生存优于评分为1或2的患者。

临床怎么用

  • 治疗前可检测格拉斯哥预后评分,用于识别同步放化疗耐受性差、毒性风险高和生存较差的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of this study was to evaluate the impact of the pretreatment Glasgow prognostic score on treatment-related toxicities, tolerance, and survival in patients with advanced head and neck cancers undergoing concurrent chemoradiotherapy (CRT). METHODS: We retrospectively analyzed and compared the clinical characteristics, toxicities, and survival of 143 patients with stages III, IVA, and IVB head and neck cancer treated with concurrent CRT according to their Glasgow prognostic score between 2007 and 2010. RESULTS: The Glasgow prognostic score was correlated with advanced tumor stage and T/N classification. Patients with a higher Glasgow prognostic score were less likely to tolerate concurrent CRT, experienced more weight loss, required tube feeding support more frequently, and had higher percentage of grade ≥3 hematological toxicities, sepsis, and toxic death. Patients with a Glasgow prognostic score of 0 had better overall and recurrence-free survival than those with a Glasgow prognostic score of 1 or 2. CONCLUSION: Pretreatment Glasgow prognostic score predicts treatment tolerance, toxicity, and survival in patients with advanced head and neck cancer undergoing concurrent CRT.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Chang PH, Yeh KY, Wang CH, et al. Impact of the pretreatment Glasgow prognostic score on treatment tolerance, toxicities, and survival in patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy. Head Neck. 2017. PMID: 28688124. doi:10.1002/hed.24853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。